Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis.
Journal
Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
14
11
2022
accepted:
25
07
2023
revised:
17
07
2023
medline:
2
11
2023
pubmed:
4
8
2023
entrez:
3
8
2023
Statut:
ppublish
Résumé
Antipsychotic drugs differ in their propensity to cause extrapyramidal side-effects (EPS), but their dose-effects are unclear. Therefore, we conducted a systematic review and dose-response meta-analysis. We searched multiple electronic databases up to 20.02.2023 for fixed-dose studies investigating 16 second-generation antipsychotics and haloperidol (all formulations and administration routes) in adults with acute exacerbations of schizophrenia. The primary outcome was the number of participants receiving antiparkinsonian medication, and if not available, the number of participants with extrapyramidal side-effects (EPS) and the mean scores of EPS rating scales were used as proxies. The effect-size was odds ratio (ORs) compared with placebo. One-stage random-effects dose-response meta-analyses with restricted cubic splines were conducted to estimate the dose-response curves. We also examined the relationship between dopamine D
Identifiants
pubmed: 37537284
doi: 10.1038/s41380-023-02203-y
pii: 10.1038/s41380-023-02203-y
pmc: PMC10618092
doi:
Substances chimiques
Antipsychotic Agents
0
Quetiapine Fumarate
2S3PL1B6UJ
Haloperidol
J6292F8L3D
Clozapine
J60AR2IKIC
Receptors, Dopamine D2
0
Types de publication
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3267-3277Informations de copyright
© 2023. The Author(s).
Références
Eur Arch Psychiatry Clin Neurosci. 2018 Oct;268(7):625-639
pubmed: 29368205
NPJ Schizophr. 2021 Sep 13;7(1):43
pubmed: 34518532
Acta Psychiatr Scand. 2006 Nov;114(5):319-27
pubmed: 17022791
Int J Epidemiol. 2002 Feb;31(1):140-9
pubmed: 11914310
Neuropsychopharmacology. 2008 Dec;33(13):3111-25
pubmed: 18418366
Front Psychiatry. 2022 Apr 06;13:832209
pubmed: 35463532
Schizophr Bull. 2022 May 7;48(3):643-654
pubmed: 35137229
Neuropharmacology. 2020 Aug 1;172:107704
pubmed: 31299229
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jun 8;84(Pt A):272-281
pubmed: 29410000
J Clin Psychopharmacol. 2004 Apr;24(2):192-208
pubmed: 15206667
Stat Med. 2000 Nov 30;19(22):3127-31
pubmed: 11113947
Br J Clin Pharmacol. 2017 Mar;83(3):612-622
pubmed: 27687785
Am J Psychiatry. 2020 Apr 1;177(4):342-353
pubmed: 31838873
Neuropsychopharmacology. 2019 Feb;44(3):598-605
pubmed: 30449883
Nat Commun. 2017 Oct 2;8(1):763
pubmed: 28970469
Eur Arch Psychiatry Clin Neurosci. 2021 Dec;271(8):1411-1413
pubmed: 34586466
J Clin Psychopharmacol. 2008 Apr;28(2):203-9
pubmed: 18344731
Acta Psychiatr Scand. 1998 Jul;98(1):65-72
pubmed: 9696517
CNS Drugs. 2015 Sep;29(9):773-99
pubmed: 26346901
Evid Based Ment Health. 2019 Nov;22(4):153-160
pubmed: 31563865
BMJ. 2008 Apr 26;336(7650):924-6
pubmed: 18436948
J Clin Psychopharmacol. 2013 Oct;33(5):675-81
pubmed: 23948784
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
JAMA Psychiatry. 2020 Oct 1;77(10):1064-1071
pubmed: 32609294
Front Psychiatry. 2022 Jan 25;12:781946
pubmed: 35145438
J Clin Psychopharmacol. 2008 Aug;28(4):392-400
pubmed: 18626265
J Clin Psychopharmacol. 2010 Oct;30(5):531-40
pubmed: 20814320
Eur Neuropsychopharmacol. 2023 Jul;72:40-49
pubmed: 37075639
BMJ Ment Health. 2023 Feb;26(1):
pubmed: 36789916
Acta Psychiatr Scand. 2021 Feb;143(2):172-180
pubmed: 33306204
Br J Psychiatry. 2010 Jul;197(1):67-72
pubmed: 20592438
Lancet Psychiatry. 2019 Sep;6(9):753-765
pubmed: 31320283
Acta Psychiatr Scand Suppl. 1970;212:11-9
pubmed: 4917967
Med Care. 1984 Dec;22(12):1101-14
pubmed: 6513619
Handb Exp Pharmacol. 2012;(212):27-52
pubmed: 23129327
Schizophr Bull. 2020 Dec 1;46(6):1439-1458
pubmed: 32415847
J Clin Epidemiol. 2006 Jan;59(1):7-10
pubmed: 16360555
Am J Psychiatry. 2021 Sep 1;178(9):838-847
pubmed: 33985348
J Clin Psychiatry. 2012 Jan;73(1):13-20
pubmed: 21733490
BMJ. 1998 Oct 31;317(7167):1181-4
pubmed: 9794850
Am J Psychiatry. 2017 Oct 1;174(10):927-942
pubmed: 28541090
Arch Gen Psychiatry. 1992 Jul;49(7):538-44
pubmed: 1352677
JAMA Psychiatry. 2021 Nov 1;78(11):1238-1248
pubmed: 34406325
Schizophr Bull. 2012 Jan;38(1):167-77
pubmed: 20513652
BMC Psychiatry. 2022 Jun 17;22(1):406
pubmed: 35715740
Psychopharmacology (Berl). 2016 Oct;233(19-20):3503-12
pubmed: 27525990
Stat Methods Med Res. 2019 May;28(5):1579-1596
pubmed: 29742975
Pharmacopsychiatry. 2018 Jan;51(1-02):9-62
pubmed: 28910830
Neuropsychopharmacology. 2020 Apr;45(5):786-792
pubmed: 31847007
Psychol Med. 2021 Feb;51(3):522-524
pubmed: 31910928
Am J Psychiatry. 2000 Apr;157(4):514-20
pubmed: 10739409
Psychol Bull. 1995 Jan;117(1):167-78
pubmed: 7870860
J Clin Psychopharmacol. 2011 Apr;31(2):160-8
pubmed: 21346616
AAPS J. 2011 Mar;13(1):121-30
pubmed: 21184291
Cochrane Database Syst Rev. 2022 Nov 24;11:CD014384
pubmed: 36420692
Neuropsychiatr Dis Treat. 2013;9:1381-92
pubmed: 24092977
Behav Brain Res. 2021 Mar 26;402:113098
pubmed: 33417992
BMC Psychiatry. 2012 Mar 20;12:20
pubmed: 22433036
J Clin Epidemiol. 2022 Feb;142:288-293
pubmed: 34380019
Res Synth Methods. 2019 Sep;10(3):398-419
pubmed: 30854785
Arch Gen Psychiatry. 2003 Oct;60(10):974-7
pubmed: 14557141
Lancet. 2019 Sep 14;394(10202):939-951
pubmed: 31303314
Int J Epidemiol. 2012 Oct;41(5):1445-59
pubmed: 23045205
Psychopharmacology (Berl). 1998 Apr;136(4):367-73
pubmed: 9600582
J Clin Psychopharmacol. 2020 May-Jun;40(3):240-249
pubmed: 32332459
PLoS One. 2010 Mar 03;5(3):e9479
pubmed: 20209133
J Clin Psychopharmacol. 2011 Aug;31(4):497-502
pubmed: 21694629
Trends Pharmacol Sci. 2004 Apr;25(4):186-92
pubmed: 15063082